Australasian Journal of Neuroscience最新文献

2022 Annual Demographic Survey of Parkinson's Disease and Movement Disorder Nurse Specialists 2022 年帕金森病和运动障碍专科护士年度人口调查

Australasian Journal of Neuroscience Pub Date : 2023-10-01 DOI: 10.21307/ajon-2023-013

Susan Williams, David Tsui, Melanie Zeppel

引用次数: 0

Surgical site infections in neurosurgical patients following cranial surgery: An integrative review 颅脑手术后神经外科患者的手术部位感染：综述

Australasian Journal of Neuroscience Pub Date : 2023-10-01 DOI: 10.21307/ajon-2023-015

Stephen Kivunja

{"title":"Surgical site infections in neurosurgical patients following cranial surgery: An integrative review","authors":"Stephen Kivunja","doi":"10.21307/ajon-2023-015","DOIUrl":"https://doi.org/10.21307/ajon-2023-015","url":null,"abstract":"Abstract Aim To synthesise the literature pertaining to surgical site infections (SSIs) in neurosurgical patients following cranial surgery. Background SSIs in neurosurgical patients following cranial surgery present a major healthcare problem for healthcare providers worldwide. The most widely reported outcomes following SSIs include increased length of inpatient stay, morbidity, mortality, higher treatment costs and increased care burden for families and caregivers. Design Integrative review. Methods Using an integrative review framework, electronic database searches were conducted in CINAHL, Embase, Medline and ProQuest from 2012 – 2022. The search was limited to peer reviewed full text publications. Reference lists of identified studies were reviewed, and additional articles were accessed. Methodological rigour for included studies was evaluated using Critical Appraisal Skills Program tools. Results Twenty articles were reviewed, and four themes emerged relating to: preoperative patient preparatory practices and SSIs; risk factors for developing SSIs post cranial surgery; patient-reported outcomes and healthcare implications; and strategies for preventing SSIs within hospital settings. Conclusion Surgical site infections post cranial surgery among neurosurgical patients can be contained through administration of pre-surgical prophylactic antibiotics, adhering to aseptic hand hygiene, utilising evidence based infection control protocols, educating neurosurgical nurse clinicians in post cranial surgical wound care, and providing tailored education for patients and families in postoperative cranial surgical wound care.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"103 1","pages":"38 - 57"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139325570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Book Review: The Trembling Mountain: A Personal Account of Kuru, Cannibals and Mad Cow Disease. 书评：颤栗之山：关于库鲁人、食人族和疯牛病的亲身经历。

Australasian Journal of Neuroscience Pub Date : 2023-10-01 DOI: 10.21307/ajon-2023-016

Linda Nichols

引用次数: 0

CTE the New News Story CTE 成为新的新闻故事

Australasian Journal of Neuroscience Pub Date : 2023-10-01 DOI: 10.21307/ajon-2023-011a

Linda Nichols

引用次数: 0

What's the story with CTE? CTE 是怎么回事？

Australasian Journal of Neuroscience Pub Date : 2023-10-01 DOI: 10.21307/ajon-2023-011b

Vicki Evans Roach

引用次数: 0

Spine Surgery and Home Again: The Nurse's Role in the Patient Journey 脊柱手术后重返家园：护士在患者旅程中的作用

Australasian Journal of Neuroscience Pub Date : 2023-10-01 DOI: 10.21307/ajon-2023-014

Kim Foxall, Catherine Hardman

{"title":"Spine Surgery and Home Again: The Nurse's Role in the Patient Journey","authors":"Kim Foxall, Catherine Hardman","doi":"10.21307/ajon-2023-014","DOIUrl":"https://doi.org/10.21307/ajon-2023-014","url":null,"abstract":"Abstract Enhanced recovery after surgery (ERAS) programs – also referred to as fast-track programs - are multidisciplinary, evidence-based perioperative pathways, designed to achieve early recovery for patients undergoing major surgery (Ali et al., 2018). ERAS utilises strategies to optimise the patient's condition for surgery and recovery. In particular, the aim is to achieve an earlier discharge from hospital for the patient and a more rapid resumption of normal activities after surgery, without an increase in complications or readmissions (Dietz et al., 2019). An essential element of ERAS programs is multidisciplinary collaboration between surgical, anaesthetic, nursing and allied health teams. While elements of ERAS may vary between surgical units and hospitals, there are many common features in the preoperative, intraoperative and postoperative phases. Minimally invasive spine surgery techniques and instrumentation have evolved rapidly over the past decade, and there is now a worldwide interest in ERAS programs for spine surgeries, including lumbar and cervical decompression and fusion procedures (Li et al., 2021). Nurses have a pivotal role in the successful implementation and sustainability of ERAS protocols because of their specialised knowledge and skill, and their constant presence throughout the patient care pathway (Wainwright et al., 2022). This publication presents learnings from the implementation of an ERAS program for minimally invasive spine surgery at Westmead Hospital, NSW.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"31 1","pages":"30 - 37"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139328841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding Parkinson's Disease: A Basic Overview 了解帕金森病：基本概述

Australasian Journal of Neuroscience Pub Date : 2023-10-01 DOI: 10.21307/ajon-2023-012

Rachael L Anderson, Adelene Choo, Sue Sharrad, Ruth Withey

{"title":"Understanding Parkinson's Disease: A Basic Overview","authors":"Rachael L Anderson, Adelene Choo, Sue Sharrad, Ruth Withey","doi":"10.21307/ajon-2023-012","DOIUrl":"https://doi.org/10.21307/ajon-2023-012","url":null,"abstract":"Abstract Parkinson's disease (PD) is a multi-system disease, with clinical features typically described across three domains: motor, non-motor, and neuropsychiatric symptoms. There is no known cause or cure for PD, and diagnosis occurs often through a process of elimination, remaining one of clinical assessment, expert opinion, and observing disease progression over time. In the absence of disease modifying therapy for PD, pharmacological treatments play a role in symptomatic relief and improving quality of life (QoL). A narrowing therapeutic window and motor fluctuations present a challenge to the pharmacological management of PD. Device assisted therapies including Duodopa, Apomorphine and deep brain stimulation are based on the concept of providing stable and continuous stimulation to minimise pulsatile sudden or unexpected fluctuations. Studies continue to demonstrate the benefit of multidisciplinary input and the impact on functional status, mood, motor abilities, cognitive performance, speech skills, independence and QoL of a person with PD. Nurses are well placed to identify complications, escalate concerns, and initiate timely referral to members of a multidisciplinary team. Understanding the clinical features of PD as well as the basic assessment and management of the disease is essential in providing holistic care and supports to maintain QoL for those with PD and their caregivers.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"14 1","pages":"9 - 23"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139331084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Apomorphine subcutaneous titration in Parkinson’s disease - the effectiveness and safety of apomorphine challenges: A Literature Review 阿波啡皮下滴注治疗帕金森病——阿波啡的有效性和安全性挑战:文献综述

Australasian Journal of Neuroscience Pub Date : 2023-05-01 DOI: 10.21307/ajon-2023-005

Amy E. Jones, Elise M Tune

{"title":"Apomorphine subcutaneous titration in Parkinson’s disease - the effectiveness and safety of apomorphine challenges: A Literature Review","authors":"Amy E. Jones, Elise M Tune","doi":"10.21307/ajon-2023-005","DOIUrl":"https://doi.org/10.21307/ajon-2023-005","url":null,"abstract":"Abstract This review examined the body of evidence to determine the efficacy of an apomorphine challenge. Its primary objective is to identify the dose of the most common adverse events involved with apomorphine challenges. The secondary objective is to determine whether a titration challenge is warranted prior to commencing Apomorphine therapy or an alternate option, such as slow titration, is more efficacious. Results: The literature review was developed using the Cochrane handbook of systematic reviews. The search yielded 157 results, only 23 were included in the final analysis. Evidence is largely lacking and traditionally anecdotal and based on clinician experience. Studies inadequately control for reporter and rater bias, have small sample sizes; high level evidence is lacking. Continuous rates range between 2-4mg/hr (Deleu, 2004) and an intermittent dose range between 4mg- 6 mg (Pahwa et al 2007); doses higher than this are likely to induce side effects. QT interval prolongation is linked with both apomorphine and domperidone use and an electrocardiogram (ECG) should be performed prior to commencing both medications. A positive result for an apomorphine challenge is determined when there is a 20% improvement from baseline score in part III of the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS- UPDRS), 30 minutes after a dose is given. Lastly, review examines a theoretical way to titrate patients using the Tomlinson levodopa conversion.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"1 1","pages":"39 - 47"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90277536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neurological Assessment: Practice Review’ 神经学评估:实践回顾

Australasian Journal of Neuroscience Pub Date : 2023-05-01 DOI: 10.21307/ajon-2023-008

Chantelle Jameson, J. A. Butler

引用次数: 0

Apomorphine and Domperidone Review 阿波啡与多潘立酮综述

Australasian Journal of Neuroscience Pub Date : 2023-05-01 DOI: 10.21307/ajon-2023-002

R. Mackinnon, V. Carroll

{"title":"Apomorphine and Domperidone Review","authors":"R. Mackinnon, V. Carroll","doi":"10.21307/ajon-2023-002","DOIUrl":"https://doi.org/10.21307/ajon-2023-002","url":null,"abstract":"Abstract Apomorphine is generally a safe and well tolerated therapy used in acute and intermittent treatment of the motor symptoms, the ‘off’ motor state in Parkinson’s disease, and there is growing evidence supporting its clinical value in non-motor symptoms. It has an excellent efficacy profile in clinical practice, though the use of the agent continues to be underutilised. One of the most common reasons of this is most likely the perception of how difficult it is to use the agent, and the management of the adverse events (AE’s). The discontinuation due to AE’s is not as common as it has been believed. Apomorphine is generally well tolerated by most patients and if AE’s do develop, they are manageable in most cases. The objective of this literature review was to examine the body of literature regarding the risk of Electrocardiogram (ECG) changes, and cardiac arrest in apomorphine challenges; and to look for safety parameters for people commencing and continuing apomorphine therapy. There is evidence that apomorphine can prolong a QTc interval, leading to cardiac arrhythmias. During the apomorphine challenge the drug domperidone is widely used to combat the side effects of nausea and vomiting, and vasodilation side effects of postural hypotension from the apomorphine. Domperidone has also been identified and studied as a medication with risks of QTc prolongation.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"100 1","pages":"6 - 13"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80351960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0